At Future Synch, we review startups regularly — not to rank them, not to pitch them, but to look at the market through two lenses at once: as an entrepreneur who builds, and as an operator who executes.
Lottie is arguably the most impressive operational story in this review series. The growth metrics are real. The product wedge was well-executed. The multi-product expansion is logical. The structural question is the one that every multi-product company faces eventually: which product are you building the company around?
Lottie executed a textbook marketplace wedge — started as a care home discovery tool, then made fee transparency a mandatory listing condition. That was an industry first and a structural moat: transparency became the cost of supply-side participation, not a feature. It changed the platform's relationship with providers from optional to necessary.
Acquiring Found CRM — software care providers already used — embedded Lottie into the operational layer of the supply side, not just the consumer search side. Real-time bed availability converted the platform from a directory into a transactional layer. The NHS bed-blocking integration deepened this further: Lottie is now used by hospital discharge teams as operational infrastructure.
Found CRM (provider ops), Seniorcare by Lottie (employer benefits), Care IQ (market intelligence) — each product monetises a different stakeholder in the same care ecosystem without requiring a new acquisition motion. The flywheel logic is structurally sound: more providers on Found means better marketplace data, which means better Care IQ, which means stronger employer benefits propositions.
Lottie didn't just build a marketplace. It embedded into the supply side's operations and then turned that operational presence into institutional infrastructure — NHS discharge teams, employer benefits, market intelligence.
Lottie is operationally impressive — but the revenue model is not publicly explicit. Is primary income from provider listing fees? Referral commissions on placements? Found CRM SaaS subscription? Seniorcare employer contracts? The answer determines the unit economics conversation with Series B investors. At this stage of growth, ambiguity around primary monetisation slows institutional conversations.
US, India, and Australia are named as expansion markets. These are not adjacent — each has distinct regulatory frameworks, care funding structures, and care home market dynamics. Attempting three geographies simultaneously before UK monetisation is maximised risks operational dilution and investor narrative fragmentation.
At Series B, investors do not buy potential across four products. They model a primary revenue anchor, unit economics, and expansion repeatability. Lottie is simultaneously a consumer marketplace, a B2B SaaS company, an employee benefits platform, and a data intelligence product. Each competes for internal resource allocation. Without a declared primary, the growth model is hard to evaluate at institutional scale.
The NHS integration is the most commercially underutilised part of Lottie's story. "Infrastructure that reduces bed-blocking" is not a consumer growth narrative — it is a public sector procurement story. That is a different category with longer contract structures, institutional defensibility, and a different class of investor. Building this narrative explicitly changes the Series B conversation from consumer marketplace to care system infrastructure.
Publish a clear monetisation breakdown. Even at a high level, naming the primary revenue driver removes ambiguity from investor and enterprise BD conversations. Clarity compounds faster than breadth of product in fundraising cycles.
Prioritise one international market, not three. The US care home market has the most structural similarity to the UK. Build a replicable launch playbook from a single geography before distributing resource across India, Australia, and the US simultaneously.
Develop the NHS and public sector narrative explicitly. "Care infrastructure that reduces bed-blocking costs the NHS" is a government procurement story with a measurable cost-reduction claim. That opens a funding and partnership category that the consumer marketplace story does not.
Position Found CRM as a standalone SaaS product with its own metrics. A dual-flywheel story — consumer marketplace plus B2B SaaS — gives Series B investors two valuation frameworks to model simultaneously, which increases the conversation ceiling.
Clarity of focus compounds faster than breadth of product. At Series B, investors model a primary revenue anchor — not a portfolio of equally weighted bets.
Lottie has built more than a marketplace. The next chapter is deciding which part of the platform they are building a company around.
The operational achievement is real. Transparency forced into an opaque industry. Supply-side embedding through CRM acquisition. NHS integration that makes Lottie public infrastructure. One million monthly users. This is not a growth story in early innings — it is a Series B story in need of a primary frame.
The structural question is not whether the products work. It is which product anchors the monetisation model, which geography gets the international expansion resource first, and how the NHS integration reframes the platform's institutional value to a different class of investor.
Answering those three questions explicitly — before the Series B process begins — is the difference between a fundraise that takes six months and one that takes twelve.
Apply for a Strategic Growth Review →